420787-66-2

Upstream product

• 6919-61-5 N-methoxy-N-methylbenzamide 
• 2117-12-6 4-(trimethylsilyl)but-3-yn-1-ol 
• 420787-57-1 [3-(2-hydroxy-ethyl)-4-trimethylsilanyl-furan-2-yl]-phenyl-methanone 
• 420787-55-9 acetoxyethylfuran 
• 420787-56-0 2-(4-trimethylsilanyl-furan-3-yl)-ethanol 
• 183155-11-5 4-(trimethylsilyl)-3-butynyl acetate 

Downstream Products

• 420787-58-2 2-[2-(2-benzoyl-4-trimethylsilanyl-furan-3-yl)-ethyl]-malonic acid diethyl ester 
• 420787-60-6 1-benzoyl-5,6-dihydro-cyclopenta[c]furan-4,4-dicarboxylic acid diethyl ester 
• 420787-59-3 2-[2-(2-benzoyl-4-iodo-furan-3-yl)-ethyl]-malonic acid diethyl ester 

Relevant academic research and scientific papers

Synthesis and biological evaluation of Ketorolac analogs

Ketorolac analogs were synthesized and biologically evaluated. For the preparation of the N-methylpyrrole Ro114-1907, and the furan Ro113-8905, a hydroxyethyl-assisted regioselective benzoylation gave intermediates (4) and (12), and subsequently a key copper-mediated ring closure gave entry to the required bicyclic compounds (7) and (15). Ro113-8905 and the thiophene Ro101-8244 significantly inhibited both the writhing response and edema formation in rat, but were less potent than Ketorolac.